CONUT score as a predictor for anamorelin efficacy in patients with cancer cachexia receiving chemotherapy.

Hironori FujiiAkitaka MakiyamaKayoko NishimuraHirotoshi IiharaChiemi HiroseKoichi OhataYunami YamadaDaichi WatanabeItaru YasufukuNaoki OkumuraYoshihiro TanakaTakao TakahashiRyo KobayashiNobuhisa MatsuhashiAkio Suzuki

Published in: Journal of pharmaceutical health care and sciences (2024)

Anamorelin may maintain or increase LBM with tolerable safety in patients with cancer cachexia undergoing chemotherapy. A low CONUT score, despite meeting criteria for cancer cachexia, is suggested as a predictor for the efficacy of anamorelin, indicating that patients with a low CONUT score may benefit from early introduction of anamorelin.

Keyphrases

locally advanced
papillary thyroid
squamous cell
chemotherapy induced
lymph node metastasis